What Is KPV?
KPV (Lysine-Proline-Valine) is a tripeptide corresponding to residues 11-13 at the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH), the 13-amino-acid parent hormone best known for its role in pigmentation and energy homeostasis. Isolated as a fragment, KPV appears to retain much of alpha-MSH’s anti-inflammatory signaling while shedding the pigmentary and metabolic activity tied to melanocortin receptor engagement elsewhere in the molecule. It has been studied almost exclusively in cell culture and rodent models, primarily in the context of intestinal inflammation, with smaller bodies of work on wound healing and mast cell biology. As of 2026, no completed human clinical trials of KPV have been published.
NF-kB Pathway Inhibition
The most consistently reported mechanism for KPV is inhibition of nuclear factor-kappa B (NF-kB), a transcription factor that governs the expression of a wide range of pro-inflammatory genes. In a 2008 Gastroenterology study, Dalmasso and colleagues found that nanomolar concentrations of KPV blocked NF-kB activation in human intestinal epithelial cells (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells stimulated with IL-1beta or TNF-alpha, evidenced by reduced NF-kB-luciferase reporter activity and preserved IkB-alpha, the inhibitory protein that normally must be degraded for NF-kB to activate. The same study reported reductions in downstream MAP kinase signaling (ERK1/2, JNK, p38) and lower IL-8 mRNA and protein output. A separate line of work using immobilized alpha-MSH(10-13) peptide, published by Kelly and colleagues in Peptides in 2005, found similar suppression of TNF-alpha-stimulated NF-kB activity, reinforcing that the C-terminal fragment alone carries meaningful anti-inflammatory signaling capacity independent of the full alpha-MSH sequence.
PepT1-Mediated Cellular Uptake
A distinguishing feature of KPV, relative to most anti-inflammatory peptides, is how it gets into cells. Dalmasso and colleagues showed that KPV competes with radiolabeled substrate for the PepT1 transporter, a proton-coupled di/tripeptide transporter normally expressed in the small intestine and upregulated in inflamed colon tissue, and that KPV taken up by cells expressing PepT1 produced stronger anti-inflammatory effects than in cells without it. This transporter-mediated route is part of why KPV has drawn interest in oral and gut-targeted delivery research: a peptide that can be absorbed and act locally at the site of intestinal inflammation is mechanistically distinct from peptides that require injection to reach systemic circulation.
Independence from Melanocortin Receptor Signaling
Unlike full-length alpha-MSH, KPV’s anti-inflammatory activity does not appear to require classical melanocortin receptor engagement. An earlier study, published in the Journal of Pharmacology and Experimental Therapeutics in 2003, compared KPV to alpha-MSH and the melanocortin agonist MTII in a mouse peritonitis model and found that KPV reduced leukocyte accumulation without increasing intracellular cAMP, the signaling response expected from melanocortin receptor activation, and its effect was not blocked by the MC3/4 receptor antagonist SHU9119. Kannengiesser and colleagues, writing in Inflammatory Bowel Diseases in 2008, extended this by testing KPV in mice lacking a functional MC1 receptor and found KPV still produced anti-inflammatory effects, including rescuing MC1R-deficient mice from death during DSS colitis. Together, these findings point to a receptor-independent, intracellular mechanism, consistent with the NF-kB and PepT1 pathway described above, as the primary driver of KPV’s activity, rather than the melanocortin receptor signaling that defines most of alpha-MSH’s other biological effects.
Gut Inflammation and IBD Models
The bulk of KPV research sits in models of inflammatory bowel disease. In DSS (dextran sodium sulfate) and TNBS (trinitrobenzene sulfonic acid) colitis models, oral KPV administration has been associated with earlier recovery of body weight, reduced colonic myeloperoxidase activity, a marker of neutrophil infiltration, and lower mRNA expression of pro-inflammatory cytokines including IL-1beta, IL-6, TNF-alpha, and IFN-gamma. Kannengiesser’s group also tested KPV in the CD45RB(hi) T-cell transfer colitis model, a chronic, adaptive-immune-driven model distinct from the acute chemical injury of DSS or TNBS, and reported comparable improvements in weight and histology. These two model systems, spanning both innate/chemical and adaptive/immune-mediated colitis, represent the strongest and most reproduced evidence base for KPV to date.
Mast Cells and Wound Healing Research
A smaller body of research looks at KPV outside the gut. Review literature on melanocortin-derived peptides describes attenuation of mast cell degranulation as one of the downstream anti-inflammatory effects attributed to C-terminal alpha-MSH fragments, alongside suppressed macrophage cytokine release. Separately, rodent skin-incision studies examining local KPV or alpha-MSH-fragment exposure have reported fewer infiltrating leukocytes and mast cells at the wound site during the early healing window, with smaller scar areas and better-organized collagen at later time points compared to untreated controls. This wound-healing work is preliminary, based on small rodent studies, and has not been replicated at the scale of the IBD literature. It should be read as an early signal rather than an established effect.
What the Research Does Not Show
It is worth being direct about the limits here. Every mechanistic and efficacy finding described above comes from cell culture or rodent models. No registered human clinical trial of KPV has been published, so there is no human data on pharmacokinetics, effective exposure, or safety at any dose. Extrapolating rodent colitis or peritonitis outcomes to human inflammatory disease involves real uncertainty; model systems like DSS colitis are useful for isolating mechanism but do not fully replicate human IBD pathophysiology. KPV is not FDA-approved for any indication and is not evaluated for safety or purity as a human therapeutic. Researchers reading this literature should treat KPV as an experimental tool with a genuinely interesting mechanism, not a validated treatment.
Research Use Only
KPV is available through FenaLife Labs for in vitro and animal model research purposes only. All batches are third-party tested and ship with a full certificate of analysis. Not intended for human consumption.
🔬 Research Compounds Referenced: KPV 10mg | BAC Water 10ml
Selected Research References
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID: 18061177
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-331. PMID: 18092346
- Kelly JM, Moir AJ, Carlson K, Yang Y, MacNeil S, Haycock JW. Immobilized alpha-melanocyte stimulating hormone 10-13 (GKPV) inhibits tumor necrosis factor-alpha stimulated NF-kappaB activity. Peptides. 2006;27(2):431-437. PMID: 16274845
- Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of Pharmacology and Experimental Therapeutics. 2003. PMID: 12750433
- Catania A, et al. Terminal Signal: Anti-Inflammatory Effects of alpha-Melanocyte-Stimulating Hormone Related Peptides Beyond the Pharmacophore. Advances in Experimental Medicine and Biology. 2010;681:79-88.